2025-07-15　恭賀張璧月醫檢師當選『第16屆桃園市醫事檢驗師公會理事長』!!! 　 2025-06-30　恭賀邱仁祥醫檢師當選『第17屆南投縣醫檢師公會理事長』!!! 　 2023-07-01　會員如有權益相關問題及對本會有任何建議或意見回饋，歡迎利用電子信箱或致電本會，謝謝您!! 　 2015-02-02　醫事檢驗師宣誓誓詞，誓詞內容請至文件下載區查閱，並請協助推廣，謝謝！　

:::

歷年稿件內容

*類別：
* 姓名：	范美玲
投稿種類：	壁報
*中文投稿標題：	以p63之表現區分原位性乳癌及侵襲性乳癌
*中文作者姓名列：
*中文服務單位：
*英文投稿標題：
*英文作者姓名列：
*英文服務單位：
* 投稿摘要：	Breast carcinoma is one of the most common neoplasms in women and is a leading cause of cancer-related deaths worldwide. But different from the treatment and prognosis of breast carcinoma in situ and invasive carcinoma. p63 is a member of the p53 gene family, and its germline mutations are associated with severe mammary developmental defects in both rodents and humans. Myoepithelial cells based only on routine hematoxylin-eosin stain may be very difficult. p63 is highly expressed in embryonic ectoderm and in the nuclei of basal regenerative cells of many epithelial tissues in the adult including skin, breast myoepithelium, oral epithelium, prostate and urothelia. We Collected 62 immunostaining of p63 in breast specimens for one year period, 40(64.5%) were p63(＋) diagnosed as cacinoma in situ, 22(35.5%) were p63(－) diagnosed as invasive breast lesions. We found that p63 expression was restricted to the nucleus, with a nucleoplasmic pattern. P63 is expressed predominantly in basal cell and squamous cell carcinomas, but not in adenocarcinomas, including those of breast and prostate. This marker, display varying cross-reactivity patterns and variably reduced expression in the myoepithelial cells bordering in situ carcinomas. Immunostaining for the myoepithelial cell marker p63 has been shown to be useful to separate noninvasive from invasive breast lesions in histologic examination.
*關鍵字1 ：	p63
*關鍵字2 ：	Immunostaining
*關鍵字3 ：	Breast
*關鍵字4 ：
*關鍵字5 ：
* 服務機關：
* 第一作者：	范美玲
* 身分字號：	*****68719
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
上傳稿件檔：	開啟檔案
審查委員意見：	無意見
審查委員意見：	ok
主任委員意見：